Report overview
Thyroid cancer is the most common endocrine tumor. Four targeted agents (vandetanib, cabozantinib, sorafenib, and lenvatinib) have attained regulatory approval for advanced thyroid cancer, and several other related agents are now commonly used off-label as first- and second-line treatments for selected patients.
This report aims to provide a comprehensive presentation of the global market for Medicine for the Treatment of Advanced Thyroid Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Medicine for the Treatment of Advanced Thyroid Cancer. This report contains market size and forecasts of Medicine for the Treatment of Advanced Thyroid Cancer in global, including the following market information:
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Sales, 2018-2023, 2024-2029, (Tons)
Global top five Medicine for the Treatment of Advanced Thyroid Cancer companies in 2022 (%)
The global Medicine for the Treatment of Advanced Thyroid Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Cabozantinib Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Medicine for the Treatment of Advanced Thyroid Cancer include Bayer, AstraZeneca, Sanofi, Exelixis Inc., Ipsen Pharma and Eisai Inc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Medicine for the Treatment of Advanced Thyroid Cancer manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Medicine for the Treatment of Advanced Thyroid Cancer Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (Tons)
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Segment Percentages, by Type, 2022 (%)
Cabozantinib
Sorafenib
Vandetanib
Lenvatinib
Global Medicine for the Treatment of Advanced Thyroid Cancer Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (Tons)
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Segment Percentages, by Application, 2022 (%)
Combination therapy
Solo Medication
Global Medicine for the Treatment of Advanced Thyroid Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (Tons)
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Medicine for the Treatment of Advanced Thyroid Cancer revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Medicine for the Treatment of Advanced Thyroid Cancer revenues share in global market, 2022 (%)
Key companies Medicine for the Treatment of Advanced Thyroid Cancer sales in global market, 2018-2023 (Estimated), (Tons)
Key companies Medicine for the Treatment of Advanced Thyroid Cancer sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
AstraZeneca
Sanofi
Exelixis Inc.
Ipsen Pharma
Eisai Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Medicine for the Treatment of Advanced Thyroid Cancer, market overview.
Chapter 2: Global Medicine for the Treatment of Advanced Thyroid Cancer market size in revenue and volume.
Chapter 3: Detailed analysis of Medicine for the Treatment of Advanced Thyroid Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Medicine for the Treatment of Advanced Thyroid Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Medicine for the Treatment of Advanced Thyroid Cancer capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
